Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease

Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease

Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are reported to reduce body fat in patients with type 2 diabetes mellitus (T2DM), and SGLT2i-induced weight reduction may help improve comorbid nonalcoholic fatty liver disease (NAFLD). This study aimed to investigate the potential benefit of SGLT2...

Full description

Bibliographic Details
Main Authors:	Won Euh, Soo Lim, Jin-Wook Kim
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-06-01
Series:	Frontiers in Endocrinology
Subjects:	type 2 diabetes mellitus sodium-glucose cotransporter 2 (SGLT2) inhibitor alanine aminotransferase body weight propensity score (PS) matching (PSM)
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2021.613389/full

Similar Items

Meta‐analysis of the effects of sodium glucose cotransporter 2 inhibitors in non‐alcoholic fatty liver disease patients with type 2 diabetes
by: Binayak Sinha, et al.
Published: (2021-02-01)

Liver function markers predict cardiovascular and renal outcomes in the CANVAS Program
by: Giulia Ferrannini, et al.
Published: (2022-07-01)

Reductions in liver enzymes are associated with anti‐hyperglycaemic and anti‐obesity effects of tofogliflozin in people with type 2 diabetes: Post‐hoc analyses
by: Toshinari Takamura, et al.
Published: (2024-01-01)

The effect of magnesium supplementation and weight loss on liver enzymes in patients with nonalcoholic fatty liver disease
by: Majid Karandish, et al.
Published: (2013-01-01)

Reasons for Discontinuing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes in Real-World Settings: The KAMOGAWA-A Study
by: Yuto Saijo, et al.
Published: (2023-11-01)

Sodium-Glucose Cotransporter-2 Inhibitors-from the Treatment of Diabetes to Therapy of Chronic Heart Failure
by: Dominik Kurczyński, et al.
Published: (2022-07-01)

The Safety and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors for Patients with Sarcopenia or Frailty: Double Edged Sword?
by: Ayami Naito, et al.
Published: (2024-01-01)

New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure
by: Juexing Li, et al.
Published: (2022-09-01)

Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin
by: Min-Koo Choi, et al.
Published: (2020-03-01)

Therapeutic Effects of Green Tea on Nonalcoholic Fatty Liver Disease in 10-16-Year-Old Children
by: Noushin Rostampour, et al.
Published: (2019-07-01)

Toxicity of Margarine on Liver Enzymes (Aspartate Amino Transferas and Alanine Amino Transferase) in Rats
by: Zahra Salemi, et al.
Published: (2012-08-01)

Sodium–Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration—A Novel Mechanism of Action
by: Anna Kochanowska, et al.
Published: (2023-06-01)

Effect of Nutmeg on Transaminase Activities in Liver and Serum of Adult Wistar rats
by: P. E. Awhin, et al.
Published: (2023-03-01)

Prevalence and risk factors of elevated alanine aminotransferase among Korean adolescents: 2001-2014
by: Ju Whi Kim, et al.
Published: (2018-05-01)

From Kidney Protection to Stroke Prevention: The Potential Role of Sodium Glucose Cotransporter-2 Inhibitors
by: Cheng-Yang Hsieh, et al.
Published: (2022-12-01)

The effects of Sodium-glucose cotransporter 2 inhibitors on adipose tissue in patients with type 2 diabetes: A meta-analysis of randomized controlled trials
by: Xindong Liu, et al.
Published: (2023-01-01)

Quality of methodological reporting of randomized clinical trials of sodium-glucose cotransporter-2 (sglt2) inhibitors
by: Hadeel Alfahmi, et al.
Published: (2017-01-01)

Clinical significance of serum alanine aminotransferase and lifestyle intervention in children with nonalcoholic fatty liver disease
by: Kyoung Ah Kwon, et al.
Published: (2016-09-01)

Euglycemic diabetic ketoacidosis associated with sodium–glucose cotransporter-2 inhibitors after surgery: A case report and review of literature
by: Mei-An Pai, et al.
Published: (2023-01-01)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis
by: Jonathan V. Mui, et al.
Published: (2021-10-01)

Association between physical activity and serum liver aminotransferases in Southwestern Iran: A Cross-sectional study
by: Sajad Badiei, et al.
Published: (2022-01-01)

Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature
by: Alexis Diaz-Ramos, et al.
Published: (2019-09-01)

The Effects of SGLT2 Inhibitors on Liver Cirrhosis Patients with Refractory Ascites: A Literature Review
by: Yasunori Miyamoto, et al.
Published: (2023-03-01)

Effects of Ashwagandha (Withania somnifera) Root Extract On Some Serum Liver Marker Enzymes (AST, ALT) In Gentamicin Intoxicated Rats
by: Nayma Sultana, et al.
Published: (2012-06-01)

Association Between Aspartate Aminotransferase to Alanine Aminotransferase Ratio and Incidence of Type 2 Diabetes Mellitus in the Japanese Population: A Secondary Analysis of a Retrospective Cohort Study
by: Chen L, et al.
Published: (2021-11-01)

Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with advanced, inoperable pancreatic adenocarcinoma: a phase 1b observational study
by: Lauren K. Park, et al.
Published: (2023-05-01)

Sodium–Glucose Cotransporter-2 Inhibitors Could Help Delay Renal Impairment in Patients with Type 2 Diabetes: A Real-World Clinical Setting
by: Gyunam Park, et al.
Published: (2022-09-01)

Effect of Sodium Glucose Cotransporter 2 Inhibitors on Renal Function in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Japan
by: Kota Yano, et al.
Published: (2020-02-01)

Association between SGLT2 (sodium-glucose cotransporter-2) inhibitors and bladder cancer in individuals with type 2 diabetes; a systematic review and meta-analysis
by: Mobin Mohammadtabar, et al.
Published: (2023-03-01)

Prevalence of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitor Prescribing in Patients with Type 2 Diabetes Mellitus and Reduced Estimated Glomerular Filtration Rate
by: Kayla Chonko, et al.
Published: (2023-06-01)

Male Rat Susceptibility for Liver and Kidney Injury
by: Sarkawt Hamad, et al.
Published: (2016-05-01)

Non-alcoholic fatty liver disease in hemochromatosis probands with iron overload and HFE p.C282Y/p.C282Y
by: James C. Barton, et al.
Published: (2023-04-01)

Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure
by: Alex Ali Sayour, et al.
Published: (2020-09-01)

The effect of obesity and Insulin Resistance on Liver Enzymes in Type2 Diabetes Mellitus
by: Baghdad Science Journal
Published: (2015-09-01)

Alteration of laboratory findings after radiofrequency ablation of hepatocellular carcinoma: relationship to severity of the underlying liver disease and the ablation volume
by: Sang-Wook Shin, et al.
Published: (2015-03-01)

Histopathological and Enzymatic Changes in Liver of Mice Treated with Tricyclazole
by: Esmail Fattahi
Published: (2017-11-01)

Association between alanine aminotransferase to high-density lipoprotein cholesterol ratio and nonalcoholic fatty liver disease: a retrospective cohort study in lean Chinese individuals
by: Changchun Cao, et al.
Published: (2024-03-01)

The Effect of Ramadan Fast on Serum liver Enzyme Levels in Iranian Adults
by: Mahshid Mohammadian, et al.
Published: (2021-11-01)

Comparison of the Ornithine Carbamyltransferase with Aspartate Aminotransferase and Alanine Aminotransferase in patients with liver diseases
by: HR.Joshaghani, et al.
Published: (2002-09-01)

Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH)
by: Ryo Goto, et al.
Published: (2019-04-01)